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Drug addiction can be defined by a three-stage cycle – binge/intoxication, with-
drawal/negative affect, and preoccupation/anticipation – that involves allostatic changes
in the brain reward and stress systems. Two primary sources of reinforcement, positive
and negative reinforcement, have been hypothesized to play a role in this allostatic process.
The negative emotional state that drives negative reinforcement is hypothesized to derive
from dysregulation of key neurochemical elements involved in the brain reward and stress
systems. Specific neurochemical elements in these structures include not only decreases
in reward system function (within-system opponent processes) but also recruitment of
the brain stress systems mediated by corticotropin-releasing factor (CRF) and dynorphin-
κ opioid systems in the ventral striatum, extended amygdala, and frontal cortex (both
between-system opponent processes). CRF antagonists block anxiety-like responses asso-
ciated with withdrawal, block increases in reward thresholds produced by withdrawal from
drugs of abuse, and block compulsive-like drug taking during extended access. Excessive
drug taking also engages the activation of CRF in the medial prefrontal cortex, paralleled by
deficits in executive function that may facilitate the transition to compulsive-like respond-
ing. Neuropeptide Y, a powerful anti-stress neurotransmitter, has a profile of action on
compulsive-like responding for ethanol similar to a CRF1 antagonist. Blockade of the κ opi-
oid system can also block dysphoric-like effects associated with withdrawal from drugs of
abuse and block the development of compulsive-like responding during extended access
to drugs of abuse, suggesting another powerful brain stress system that contributes to
compulsive drug seeking. The loss of reward function and recruitment of brain systems
provide a powerful neurochemical basis that drives the compulsivity of addiction.
Keywords: opponent process, extended amygdala, corticotropin-releasing factor, dynorphin, reward, compulsive,
withdrawal, prefrontal cortex
WHAT IS ADDICTION?
Addiction can be defined as a chronic, relapsing disorder that has
been characterized by (i) a compulsion to seek and take drugs, (ii)
loss of control over drug intake, and (iii) emergence of a nega-
tive emotional state (e.g., dysphoria, anxiety, and irritability) that
defines a motivational withdrawal syndrome when access to the
drug is prevented (1). The occasional, limited, recreational use
of a drug is clinically distinct from escalated drug use, the loss
of control over drug intake, and the emergence of compulsive
drug-seeking behavior that characterize addiction.
Addiction has been conceptualized as a three-stage cycle –
binge/intoxication, withdrawal/negative affect, and preoccupa-
tion/anticipation – that worsens over time and involves allostatic
changes in the brain reward and stress systems. Two primary
sources of reinforcement, positive and negative reinforcement,
have been hypothesized to play a role in this allostatic process. Pos-
itive reinforcement is defined as the process by which presentation
of a stimulus increases the probability of a response; negative rein-
forcement is defined as the process by which removal of an aversive
stimulus (or negative emotional state of withdrawal in the case of
addiction) increases the probability of a response. Reward is opera-
tionally defined similarly to positive reinforcement as any stimulus
that increases the probability of a response but also has a positive
hedonic effect. Different theoretical perspectives from experimen-
tal psychology (positive and negative reinforcement frameworks),
social psychology (self-regulation failure framework), and neu-
robiology (counteradaptation and sensitization frameworks) can
be superimposed on the stages of the addiction cycle (1). These
stages are thought to feed into each other, become more intense,
and ultimately lead to the pathological state known as addiction
(Figure 1). The neural substrates for the two sources of reinforce-
ment that play a key role in the allostatic neuroadaptations derive
from two key motivational systems required for survival: the brain
reward and brain stress systems.
BRAIN REWARD SYSTEMS
Comprehension of a brain reward system was greatly facilitated
by the discovery of electrical brain stimulation reward by Olds
and Milner (2). Brain stimulation reward involves widespread
neurocircuitry throughout the brain, but the most sensitive sites
include the trajectory of the medial forebrain bundle that con-
nects the ventral tegmental area with the basal forebrain [(2–4);
Figure 2]. All drugs of abuse acutely decrease brain stimulation
reward thresholds [i.e., increase or facilitate reward; (5)]. When
drugs are administered chronically, withdrawal from drugs of
abuse increases reward thresholds (decrease reward). Although
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FIGURE 1 |Theoretical framework relating addiction cycle to
motivation for drug seeking. The figure shows the change in the relative
contribution of positive and negative reinforcement constructs during the
development of substance dependence [taken with permission from Ref.
(61)].
much emphasis was initially placed on the role of ascending
monoamine systems, particularly the dopamine system, in the
medial forebrain bundle in mediating brain stimulation reward,
other non-dopaminergic systems in the medial forebrain bun-
dle clearly play a key role (6–8). Indeed, the role of dopamine
is hypothesized to be more indirect. Many studies suggest that
activation of the mesolimbic dopamine system attaches incentive
salience to stimuli in the environment (9–11) to drive the perfor-
mance of goal-directed behavior (12) or activation in general (13,
14), and work concerning the acute reinforcing effects of drugs of
abuse supports this hypothesis.
Our knowledge of the neurochemical substrates that mediate
the acute reinforcing effects of drugs of abuse has contributed sig-
nificantly to our knowledge of the brain reward system. These sub-
strates include connections of the medial forebrain bundle reward
system with primary contributions from the ventral tegmental
area, nucleus accumbens, and amygdala. Much evidence supports
the hypothesis that psychostimulant drugs dramatically activate
the mesolimbic dopamine system (projections from the ventral
tegmental area to the nucleus accumbens) during limited-access
drug self-administration and that this mechanism is critical for
mediating the rewarding effects of cocaine, amphetamines, and
nicotine. However, evidence supports both dopamine-dependent
and dopamine-independent neural substrates for opioid and alco-
hol reward (15–17). Serotonin systems, particularly those involv-
ing serotonin 5-HT1B receptor activation in the nucleus accum-
bens, have also been implicated in the acute reinforcing effects
of psychostimulant drugs, whereas µ-opioid receptors in both
the nucleus accumbens and ventral tegmental area mediate the
reinforcing effects of opioids. Opioid peptides in the ventral stria-
tum and amygdala have been hypothesized to mediate the acute
reinforcing effects of ethanol self-administration, largely based on
the effects of opioid antagonists. Inhibitory γ-aminobutyric acid
(GABA) systems are activated both pre- and postsynaptically in
the amygdala by ethanol at intoxicating doses, and GABA receptor
FIGURE 2 | Neurotransmitter pathways and receptor systems
implicated in the acute reinforcing effects of drugs of abuse within the
medial forebrain bundle. A sagittal rodent brain section is shown. The
medial forebrain bundle represents ascending and descending projections
between the ventral forebrain (nucleus accumbens, olfactory tubercle, and
septal area) and ventral midbrain (ventral tegmental area; not shown in
figure for clarity). Cocaine and amphetamines increase dopamine levels in
the nucleus accumbens and amygdala via direct actions on dopamine
terminals. Opioids activate endogenous opioid receptors in the ventral
tegmental area, nucleus accumbens, and amygdala. Opioids also facilitate
the release of dopamine in the nucleus accumbens via actions either in the
ventral tegmental area or nucleus accumbens but are also hypothesized to
activate elements independent of the dopamine system. Alcohol activates
GABAA receptors or enhances GABA release in the ventral tegmental area,
nucleus accumbens, and amygdala. Alcohol is also hypothesized to facilitate
the release of opioid peptides in the ventral tegmental area, nucleus
accumbens, and central nucleus of the amygdala. Alcohol facilitates the
release of dopamine in the nucleus accumbens via an action either in the
ventral tegmental area or nucleus accumbens. Nicotine activates nicotinic
acetylcholine receptors in the ventral tegmental area, nucleus accumbens,
and amygdala either directly or indirectly via actions on interneurons.
Cannabinoids activate cannabinoid CB1 receptors in the ventral tegmental
area, nucleus accumbens, and amygdala. Cannabinoids facilitate the
release of dopamine in the nucleus accumbens via an unknown
mechanism, either in the ventral tegmental area or nucleus accumbens. The
blue arrows represent the interactions within the extended amygdala
system hypothesized to play a key role in psychostimulant reinforcement.
AC, anterior commissure; AMG, amygdala; ARC, arcuate nucleus; BNST,
bed nucleus of the stria terminalis; Cer, cerebellum; C-P, caudate-putamen;
DMT, dorsomedial thalamus; FC, frontal cortex; Hippo, hippocampus; IF,
inferior colliculus; LC, locus coeruleus; LH, lateral hypothalamus; MFB,
medial forebrain bundle; N Acc., nucleus accumbens; OT, olfactory tract;
PAG, periaqueductal gray; RPn, reticular pontine nucleus; SC, superior
colliculus; SNr, substantia nigra pars reticulata; VP, ventral pallidum; VTA,
ventral tegmental area [taken with permission from Ref. (183)].
antagonists block ethanol self-administration [for comprehensive
reviews, see (16, 17)].
For the binge/intoxication stage of the addiction cycle, stud-
ies of the acute reinforcing effects of drugs of abuse per se have
identified key neurobiological substrates. Evidence is strong for
a role for dopamine in the acute reinforcing actions of psychos-
timulants, opioid peptide receptors in the acute reinforcing effects
of opioids, and GABA and opioid peptides in the acute reinforc-
ing actions of alcohol. Important anatomical circuits include the
mesocorticolimbic dopamine system that originates in the ventral
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tegmental area and local opioid peptide systems, both of which
converge on the nucleus accumbens (17).
BRAIN STRESS SYSTEMS
The brain stress systems can be defined as neurochemical systems
that are activated during exposure to acute stressors or in a chronic
state of stress and mediate species-typical behavioral responses.
These behavioral responses in animals range from freezing to flight
and typically have face and predictive validity for similar behavior
responses in humans. For example, animals exposed to a stressor
will show an enhanced freezing response to a conditioned fear
stimulus, an enhanced startle response to a startle stimulus, avoid-
ance of open areas, open arms, or height, and enhanced species-
typical responses to an aversive stimulus (e.g., burying a shock
probe in the defensive burying test). Key neuronal/neurochemical
systems with circumscribed neurocircuitry that mediate behav-
ioral responses to stressors include glucocorticoids, corticotropin-
releasing factor (CRF), norepinephrine, and dynorphin, and key
neurochemical systems that act in opposition to the brain stress
systems include neuropeptide Y (NPY), nociceptin, and endo-
cannabinoids [for reviews, see (18–20)]. For the purposes of this
review, two brain stress systems with prominent roles in driving
the dark side of addiction will be considered: CRF and dynorphin.
CORTICOTROPIN-RELEASING FACTOR
Corticotropin-releasing factor is a 41-amino-acid polypeptide
that controls hormonal, sympathetic, and behavioral responses
to stressors (21, 22). Central administration of CRF mimics the
behavioral response to activation and stress in rodents, and admin-
istration of competitive CRF receptor antagonists generally has
anti-stress effects [for reviews, see (23–26)]. Two major CRF recep-
tors have been identified, with CRF1 receptor activation associated
with increased stress responsiveness (27) and CRF2 receptor acti-
vation associated with decreases in feeding and decreases in stress
responsiveness (28, 29), although there is some controversy in
this area (30). CRF neurons are present in the neocortex, the
extended amygdala, the medial septum, the hypothalamus, the
thalamus, the cerebellum, and autonomic midbrain and hind-
brain nuclei (31). Extensive research has been performed on
CRF neurons in the paraventricular nucleus of the hypothal-
amus (PVN), central nucleus of the amygdala (CeA), and bed
nucleus of the stria terminalis (BNST), demonstrating a key role
for PVN CRF neurons in controlling the pituitary adrenal response
to stress (32) and a key role for BNST and CeA CRF in mediat-
ing the negative affective responses to stress and drug withdrawal
(33).
The neuroanatomical entity termed the extended amygdala
(34) may represent a common anatomical substrate that integrates
brain arousal-stress systems with hedonic processing systems to
produce the neuroadaptations associated with the development of
addiction (see below). The extended amygdala is composed of the
CeA, BNST, and a transition zone in the medial (shell) subregion
of the nucleus accumbens. Each of these regions has cytoarchi-
tectural and circuitry similarities (34). The extended amygdala
receives numerous afferents from limbic structures, such as the
basolateral amygdala and hippocampus, and sends efferents to
the medial part of the ventral pallidum and a large projection to
the lateral hypothalamus, thus further defining the specific brain
areas that interface classical limbic (emotional) structures with the
extrapyramidal motor system (35). CRF in the extended amygdala
has long been hypothesized to play a key role not only in fear con-
ditioning (36, 37) but also in the emotional component of pain
processing (38).
DYNORPHIN-κ OPIOID SYSTEM
Dynorphins are opioid peptides that derive from the prodynor-
phin precursor and contain the leucine (leu)-enkephalin sequence
at the N -terminal portion of the molecule and are the presumed
endogenous ligands for the κ opioid receptor (39). Dynorphins are
widely distributed in the central nervous system (40) and play a
role in neuroendocrine regulation, pain regulation, motor activity,
cardiovascular function, respiration, temperature regulation, feed-
ing behavior, and stress responsivity (41). Dynorphins bind to all
three opioid receptors but show a preference for κ receptors (39).
Dynorphin-κ receptor system activation produces some actions
that are similar to other opioids (analgesia) but others oppo-
site to those of µ opioid receptors in the motivational domain.
Dynorphins produce aversive dysphoric-like effects in animals
and humans and have been hypothesized to mediate negative
emotional states (42–45).
Dopamine receptor activation in the nucleus accumbens shell
stimulates a cascade of events that ultimately lead to cyclic adeno-
sine monophosphate response element-binding protein (CREB)
phosphorylation and subsequent alterations in gene expression,
notably the activation of the expression of prodynorphin mRNA.
Subsequent activation of dynorphin systems has been hypothe-
sized to feed back to decrease dopamine release in the mesolimbic
dopamine system (46–50) and glutamate release in the nucleus
accumbens (51, 52). Both of these changes may contribute to the
dysphoric syndrome associated with cocaine dependence. In vivo
microdialysis studies have also provided evidence that κ opi-
oid receptors located in the prefrontal cortex (PFC) and ventral
tegmental area also regulate the basal activity of mesocortical
dopamine neurons (53, 54). In the extended amygdala, enhanced
dynorphin action may also activate brain stress responses, such as
CRF (55), or CRF in turn may activate dynorphin (56, 57).
DYNAMIC CHANGES IN REWARD: OPPONENT PROCESS
Changes in reinforcement were inextricably linked with hedonic,
affective, or emotional states in addiction in the context of tempo-
ral dynamics by Solomon’s opponent-process theory of motiva-
tion. Solomon and Corbit (58) postulated that hedonic, affective,
or emotional states, once initiated, are automatically modulated
by the central nervous system through mechanisms that reduce
the intensity of hedonic feelings. The a-process includes affective
or hedonic habituation (or tolerance), and the b-process includes
affective or hedonic withdrawal (abstinence). The a-process in
drug use consists of positive hedonic responses, occurs shortly
after the presentation of a stimulus, correlates closely with the
intensity, quality, and duration of the reinforcer, and shows tol-
erance. In contrast, the b-process in drug use appears after the
a-process has terminated, consists of negative hedonic responses,
and is sluggish in onset, slow to build up to an asymptote, slow
to decay, and gets larger with repeated exposure. The thesis we
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have elaborated is that there is a neurocircuitry change in spe-
cific neurochemical systems that account for the b-process. Such
opponent processes are hypothesized to begin early in drug tak-
ing, reflecting not only deficits in brain reward system function
but also the recruitment of brain stress systems. Furthermore, we
hypothesize that the recruitment of brain stress systems forms
one of the major sources of negative reinforcement in addiction.
Finally, we have hypothesized that such changes result not in a
return to homeostasis of reward/stress function but in allostasis
of reward/stress function that continues to drive the addiction
process (Figure 3).
Allostasis, originally conceptualized to explain persistent mor-
bidity of arousal and autonomic function, can be defined as“stabil-
ity through change.”Allostasis involves a feed-forward mechanism
rather than the negative feedback mechanisms of homeostasis,
with continuous reevaluation of need and continuous readjust-
ment of all parameters toward new set points. An allostatic state
has been defined as a state of chronic deviation of the regulatory
system from its normal (homeostatic) operating level (15). Allo-
static load was defined as the “long-term cost of allostasis that
accumulates over time and reflects the accumulation of damage
that can lead to pathological states” (59).
Opponent process-like negative emotional states have been
characterized in humans by acute and protracted abstinence
FIGURE 3 | (A)The standard pattern of affective dynamics produced by
(left ) a relatively novel unconditioned stimulus (i.e., in a non-dependent
state) and (right ) a familiar, frequently repeated unconditioned stimulus
(i.e., in a dependent state) [taken with permission from Ref. (184)]. (B)The
changes in the affective stimulus (state) in an individual with repeated
frequent drug use that may represent a transition to an allostatic state in
the brain reward systems and, by extrapolation, a transition to addiction.
Note that the apparent b-process never returns to the original homeostatic
level before drug taking is reinitiated, thus creating a greater and greater
allostatic state in the brain reward system. In other words, the
counteradaptive opponent-process (b-process) does not balance the
activational process (a-process) but in fact shows a residual hysteresis.
While these changes are exaggerated and condensed over time in the
present conceptualization, the hypothesis here is that even during
post-detoxification, a period of “protracted abstinence,” the reward system
is still bearing allostatic changes. In the non-dependent state, reward
experiences are normal, and the brain stress systems are not greatly
engaged. During the transition to the state known as addiction, the brain
reward system is in a major underactivated state while the brain stress
system is highly activated [taken with permission from Ref. (15)].
from all major drugs of abuse (60–62). Similar results have been
observed in animal models with all major drugs of abuse using
intracranial self-stimulation (ICSS) as a measure of hedonic tone.
Withdrawal from chronic cocaine (63),amphetamine (64),opioids
(65), cannabinoids (66), nicotine (67), and ethanol (68) leads to
increases in reward threshold during acute abstinence, and some
of these elevations in threshold can last for up to 1 week (69).
These observations lend credence to the hypothesis that opponent
processes in the hedonic domain have an identifiable neurobio-
logical basis and provide an impetus for defining the mechanisms
involved. Understanding the mechanisms that drive this increase
in reward thresholds is key to understanding the mechanisms that
drive negative reinforcement in addiction.
Such elevations in reward threshold begin rapidly and can
be observed within a single session of self-administration (70),
bearing a striking resemblance to human subjective reports of
acute withdrawal. Dysphoria-like responses also accompany acute
opioid and ethanol withdrawal (71, 72). Here, naloxone adminis-
tration following single injections of morphine increased reward
thresholds, measured by ICSS, and increased thresholds with
repeated morphine and naloxone-induced withdrawal experi-
ence (71). Similar results were observed during repeated acute
withdrawal from ethanol (72).
NEUROADAPTATIONS RESPONSIBLE FOR OPPONENT
PROCESS
One hypothesis is that drug addiction progresses from a source of
positive reinforcement that may indeed involve a form of sensiti-
zation of incentive salience, as argued by Robinson and Berridge
(9), to sensitization of opponent processes that set up a power-
ful negative reinforcement process. A further elaboration of this
hypothesis is that there are both within- and between-system neu-
roadaptations to excessive activation of the reward system at the
neurocircuitry level. Within-system neuroadaptations are defined
as the process by which the primary cellular response element to
the drug (circuit A) itself adapts to neutralize the drug’s effects.
Persistence of the opposing effects after the drug disappears pro-
duces adaptation. A between-system neuroadaptation is a circuitry
change, in which B circuits (i.e., the stress or anti-reward circuits)
are activated by circuit A (i.e., the reward circuit). In the present
treatise, within-system neuroadaptations can dynamically interact
with a between-system neuroadaptation, in which circuit B (i.e.,
the anti-reward circuit) is activated either in parallel or in series to
suppress the activity of circuit A (see below).
ANIMAL MODELS OF THE TRANSITION TO AN ADDICTION-LIKE STATE
AS DEFINED BY ESCALATION IN DRUG SELF-ADMINISTRATION WITH
PROLONGED ACCESS
A progressive increase in the frequency and intensity of drug use
is one of the major behavioral phenomena that characterize the
development of addiction and has face validity with the crite-
ria of the Diagnostic and Statistical Manual of Mental Disorders,
4th edition (DSM-IV): “The substance is often taken in larger
amounts and over a longer period than was intended” (Ameri-
can Psychological Association, 1994). A framework with which
to model the transition from drug use to drug addiction can
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be found in recent animal models of prolonged access to intra-
venous cocaine self-administration. Historically, animal models
of cocaine self-administration involved the establishment of sta-
ble behavior from day to day to allow the reliable interpretation
of data provided by within-subject designs aimed at exploring the
neuropharmacological and neurobiological bases of the reinforc-
ing effects of acute cocaine. Up until 1998, after the acquisition of
self-administration, rats were typically allowed access to cocaine
for 3 h or less per day to establish highly stable levels of intake
and patterns of responding between daily sessions. This was a use-
ful paradigm for exploring the neurobiological substrates for the
acute reinforcing effects of drugs of abuse.
However, in an effort to explore the possibility that differen-
tial access to drugs of abuse may have more face validity for
the compulsive-like responding observed in addiction, animals
have been allowed extended access to all major drugs of abuse
(Figure 4). Increased intake was observed in the extended-access
group for intravenous cocaine, methamphetamine, heroin, and
nicotine and oral alcohol during extended access and dependence
(73–79). For example, when animals were allowed access for 1
and 6 h to different doses of cocaine, after escalation, both the
long-access (LgA) and short-access (ShA) animals titrated their
cocaine intake, but LgA rats consistently self-administered almost
twice as much cocaine at any dose tested, further suggesting an
upward shift in the set point for cocaine reward in the escalated
animals (80–82).
Consistent with the hypothesis that extended access to drugs
of abuse produces compulsive-like responding, in which animals
will “continue to respond in the face of adverse consequences”
(another DSM-IV criteria for Substance Dependence), animals
with extended access that show escalation in self-administration
also show increased responding on a progressive-ratio schedule
of reinforcement [(83–85); Figure 5]. Changes in the reinforcing
and incentive effects of drug intake that are consistent with the
increases in progressive-ratio responding have been observed fol-
lowing extended access and include increased drug-induced rein-
statement after extinction, a decreased latency to goal time in a
runway model for drug reward, and responding in the face of
punishment (86–92). Altogether, these results suggest that drug
taking with extended-access changes the motivation to seek the
drug. Some have argued that enhanced drug taking reflects a
sensitization of reward (93), but studies of locomotor sensitiza-
tion suggest that locomotor sensitization occurs independently
of escalation (94–96). The increased brain reward thresholds and
neuropharmacological studies outlined below argue for a reward
deficit state that drives the increased drug taking during extended
access.
ANIMALS ESCALATE THEIR INTAKE OF DRUGS WITH EXTENDED
ACCESS, WITH A PARALLEL INCREASE IN REWARD THRESHOLDS
The hypothesis that compulsive cocaine use is accompanied by a
chronic perturbation in brain reward homeostasis has been tested
in animal models of escalation in drug intake with prolonged
access combined with measures of brain stimulation reward
thresholds. Animals implanted with intravenous catheters and
allowed differential access to intravenous self-administration of
cocaine showed increases in cocaine self-administration from day
to day in the LgA group (6 h; LgA) but not in the ShA group (1 h;
ShA). The differential exposure to cocaine self-administration had
dramatic effects on reward thresholds that progressively increased
in LgA rats but not ShA or control rats across successive self-
administration sessions (97). Elevations in baseline reward thresh-
olds temporally preceded and were highly correlated with escala-
tion in cocaine intake (Figure 6). Post-session elevations in reward
thresholds failed to return to baseline levels before the onset of each
subsequent self-administration session, thereby deviating more
and more from control levels. The progressive elevation in reward
thresholds was associated with a dramatic escalation in cocaine
consumption that was observed previously (97). Similar results
have been observed with extended access to methamphetamine
(98) and heroin (99). Rats allowed 6 h access to methamphetamine
or 23 h access to heroin also showed a time-dependent increase in
reward thresholds that paralleled the increases in heroin intake
(Figure 6). Similar results of parallel increases in brain reward
thresholds with escalation of nicotine intake have been observed
with extended access to nicotine (100).
BRAIN REWARD SYSTEM SUBSTRATES FOR THE NEGATIVE
REINFORCEMENT ASSOCIATED WITH ADDICTION
(WITHIN-SYSTEM NEUROADAPTATIONS)
The withdrawal/negative affect stage can be defined as the pres-
ence of motivational signs of withdrawal in humans, including
chronic irritability, physical pain, emotional pain [i.e., hyperkat-
ifeia; (101)], malaise, dysphoria, alexithymia, and loss of motiva-
tion for natural rewards. It is characterized in animals by increases
in reward thresholds during withdrawal from all major drugs of
abuse. More compelling, as noted above, in animal models of the
transition to addiction, similar changes in brain reward thresh-
olds occur that temporally precede and are highly correlated with
escalation in drug intake (97–99). Such acute withdrawal is asso-
ciated with decreased activity of the mesocorticolimbic dopamine
system, reflected by electrophysiological recordings and in vivo
microdialysis [(102–104); Figure 7].
Human imaging studies of individuals with addiction during
withdrawal or protracted abstinence have generated results that are
consistent with animal studies. There are decreases in dopamine
D2 receptors (hypothesized to reflect hypodopaminergic func-
tioning), hyporesponsiveness to dopamine challenge (105), and
hypoactivity of the orbitofrontal-infralimbic cortex system (105).
These are hypothesized to be within-system neuroadaptations that
may reflect presynaptic release or postsynaptic receptor plasticity.
In the context of chronic alcohol administration, multiple mol-
ecular mechanisms have been hypothesized to counteract the acute
effects of ethanol that could be considered within-system neuroad-
aptations. For example, chronic ethanol decreases γ-aminobutyric
acid (GABA) receptor function, possibly through downregula-
tion of the α1 subunit (106, 107). Chronic ethanol also decreases
the acute inhibition of adenosine reuptake [i.e., tolerance devel-
ops to the inhibition of adenosine by ethanol; (108)]. Perhaps
more relevant to the present treatise, whereas acute ethanol acti-
vates adenylate cyclase, withdrawal from chronic ethanol decreases
CREB phosphorylation in the amygdala and is linked to decreases
in the function of NPY and anxiety-like responses observed during
acute ethanol withdrawal (109, 110).
www.frontiersin.org August 2013 | Volume 4 | Article 72 | 5
Koob Addiction reward and stress disorders
FIGURE 4 | (A) Effect of drug availability on cocaine intake (mean±SEM). In
long-access (LgA) rats (n=12) but not short-access (ShA) rats (n=12), the
mean total cocaine intake started to increase significantly from session 5
(p<0.05; sessions 5–22 compared with session 1) and continued to increase
thereafter (p<0.05; session 5 compared with sessions 8–10, 12, 13, and
17–22) [taken with permission from Ref. (74)]. (B) Effect of drug availability on
total intravenous heroin self-infusions (mean±SEM). During the escalation
phase, rats had access to heroin (40µg per infusion) for 1 h (ShA rats, n=5–6)
or 11 h per session (LgA rats, n=5–6). Regular 1 h (ShA rats) or 11 h (LgA rats)
sessions of heroin self-administration were performed 6 days a week. The
dotted line indicates the mean±SEM number of heroin self-infusions in LgA
rats during the first 11 h session. *p<0.05, different from the first session
(paired t -test) [taken with permission from Ref. (73)]. (C) Effect of extended
access to intravenous methamphetamine on self-administration as a function
of daily sessions in rats trained to self-administer 0.05 mg/kg/infusion of
intravenous methamphetamine during the 6 h session. ShA, 1 h session
(n=6). LgA, 6 h session (0.05 mg/kg/infusion, n=4). **p<0.01, compared
with day 1 [taken with permission from Ref. (75)]. (D) Nicotine intake
(mean±SEM) in rats that self-administered nicotine under a fixed-ratio (FR) 1
schedule in either 21 h (LgA) or 1 h (ShA) sessions. LgA rats increased their
nicotine intake on an intermittent schedule with 24–48 h breaks between
sessions, whereas LgA rats on a daily schedule did not. The left shows the
total number of nicotine infusions per session when the intermittent schedule
included 24 h breaks between sessions. The right shows the total number of
nicotine infusions per session when the intermittent schedule included 48 h
breaks between sessions. #p<0.05, compared with baseline; *p<0.05,
compared with daily self-administration group. n=10 per group [taken with
permission from Ref. (185)]. (E) Ethanol self-administration in
ethanol-dependent and non-dependent animals. The induction of ethanol
dependence and correlation of limited ethanol self-administration before and
excessive drinking after dependence induction following chronic intermittent
ethanol vapor exposure is shown. ***p<0.001, significant group× test
session interaction. With all drugs, escalation is defined as a significant
increase in drug intake within-subjects in extended-access groups, with no
significant changes within-subjects in limited-access groups [taken with
permission from Ref. (186)].
BRAIN STRESS SYSTEM SUBSTRATES FOR THE NEGATIVE
REINFORCEMENT ASSOCIATED WITH ADDICTION
(BETWEEN-SYSTEM NEUROADAPTATIONS)
Brain neurochemical systems involved in arousal-stress mod-
ulation have been hypothesized to be engaged within the
neurocircuitry of the brain stress systems in an attempt to over-
come the chronic presence of the perturbing drug and restore
normal function despite the presence of drug (18). Both the
hypothalamic-pituitary-adrenal (HPA) axis and extrahypothala-
mic brain stress system mediated by CRF are dysregulated by
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FIGURE 5 | (A) Dose-response function of cocaine by rats responding under a
progressive-ratio schedule. Test sessions under a progressive-ratio schedule
ended when rats did not achieve reinforcement within 1 h. The data are
expressed as the number of injections per session on the left axis and ratio
per injection on the right axis. *p<0.05, compared with ShA rats at each
dose of cocaine [taken with permission from Ref. (84)]. (B) Responding for
heroin under a progressive-ratio schedule of reinforcement in ShA and LgA
rats. *p<0.05, LgA significantly different from LgA [Modified with
permission from Ref. (187)]. (C) Dose-response for methamphetamine under
a progressive-ratio schedule. Test sessions under a progressive-ratio schedule
ended when rats did not achieve reinforcement within 1 h. *p<0.05,
**p<0.01, LgA significantly different from ShA [Modified from Ref. (188)].
(D) Breakpoints on a progressive-ratio schedule in long-access (LgA) rats that
self-administered nicotine with 48 h abstinence between sessions. LgA rats
on an intermittent schedule reached significantly higher breakpoints than LgA
rats that self-administered nicotine daily. The data are expressed as
mean±SEM. *p<0.05. n=9 rats per group [taken with permission from
Ref. (185)]. (E) Mean (±SEM) breakpoints for ethanol while in non-dependent
and ethanol-dependent states. **p<0.01, main effect of vapor exposure on
ethanol self-administration [taken with permission from Ref. (85)].
chronic administration of all major drugs with dependence or
abuse potential, with a common response of elevated adreno-
corticotropic hormone, corticosterone, and amygdala CRF during
acute withdrawal (24, 69, 111–116). Indeed, activation of the HPA
response may be an early dysregulation associated with excessive
drug taking that ultimately“sensitizes”the extrahypothalamic CRF
systems (33, 92).
As noted above, the excessive release of dopamine and opioid
peptides produces subsequent activation of dynorphin systems,
which has been hypothesized to feed back to decrease dopamine
release and also contribute to the dysphoric syndrome associ-
ated with cocaine dependence (48). Dynorphins produce aver-
sive dysphoric-like effects in animals and humans and have been
hypothesized to mediate negative emotional states (42–45).
A common response to acute withdrawal and protracted absti-
nence from all major drugs of abuse is the manifestation of
anxiety-like responses that are reversed by CRF antagonists. With-
drawal from repeated administration of cocaine produces an
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FIGURE 6 | (A) Relationship between elevation in ICSS reward thresholds
and cocaine intake escalation (Left ). Percent change from baseline
response latencies (3 h and 17–22 h after each self-administration session;
first data point indicates 1 h before the first session) (Right ). Percent
change from baseline ICSS thresholds. *p<0.05, compared with
drug-naive and/or ShA rats (tests for simple main effects) [taken with
permission from Ref. (97)]. (B) Unlimited daily access to heroin escalated
heroin intake and decreased the excitability of brain reward systems (Left ).
Heroin intake (±SEM; 20µg per infusion) in rats during limited (1 h) or
unlimited (23 h) self-administration sessions. ***p<0.001, main effect of
access (1 or 23 h) (Right ). Percent change from baseline ICSS thresholds
(±SEM) in 23 h rats. Reward thresholds, assessed immediately after each
daily 23 h self-administration session, became progressively more
elevated as exposure to self-administered heroin increased across
sessions. *p<0.05, main effect of heroin on reward thresholds [taken
with permission from Ref. (99)]. (C) Escalation in methamphetamine
self-administration and ICSS in rats. Rats were daily allowed to receive
ICSS in the lateral hypothalamus 1 h before and 3 h after intravenous
methamphetamine self-administration with either 1 or 6 h access (Left ).
Methamphetamine self-administration during the first hour of each
session (Right ). ICSS measured 1 h before and 3 h after
methamphetamine self-administration. *p<0.05, **p<0.01,
***p<0.001, compared with session 1. #p<0.05, compared with LgA 3 h
after [taken with permission from Ref. (98)].
anxiogenic-like response in the elevated plus maze and defensive
burying test, both of which are reversed by administration of CRF
receptor antagonists (117, 118). Opioid dependence also produces
irritability-like effects that are reversed by CRF receptor antago-
nists (119, 120). Ethanol withdrawal produces anxiety-like behav-
ior that is reversed by intracerebroventricular administration of
CRF1/CRF2 peptidergic antagonists (121) and small-molecule
CRF1 antagonists (122–124) and intracerebral administration of a
peptidergic CRF1/CRF2 antagonist into the amygdala (125). Thus,
some effects of CRF antagonists have been localized to the CeA
(125). Precipitated withdrawal from nicotine produces anxiety-
like responses that are also reversed by CRF antagonists (77, 126).
CRF antagonists injected intracerebroventricularly or systemically
also block the potentiated anxiety-like responses to stressors
observed during protracted abstinence from chronic ethanol
(127–131).
Another measure of negative emotional states during drug
withdrawal in animals is conditioned place aversion, in which
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FIGURE 7 | (A)The left panel shows the effect of ethanol withdrawal on
absolute extracellular dopamine concentrations in the nucleus accumbens
in ethanol-withdrawn rats. The middle and right panels show the
spontaneous activity of antidromically identified ventral tegmental
area-nucleus accumbens dopamine neurons in control (middle) and
ethanol-withdrawn (right ) rats [taken with permission from Ref. (102)]. (B)
The left panel shows individual firing rates of antidromically identified
ventral tegmental area-nucleus accumbens dopamine neurons recorded
from morphine-withdrawn and control rats. Each circle represents the
mean firing of at least a 5-min recording. Horizontal lines indicate the
mean activity. The middle and right panels show the spontaneous activity
of a selected number (4) or antidromically identified ventral tegmental
area-nucleus accumbens dopamine neurons in control (middle) and
morphine-withdrawn (right ) rats. Each panel represents the neuronal
activity of a single cell. Recordings in both cases were obtained 24 h after
the last morphine and saline administration, respectively [taken with
permission from Ref. (103)]. (C) Firing rates of dopamine cells in the
ventral tegmental area following 1–10 days of withdrawal from chronic
nicotine treatment (6 mg/kg/day for 12 days). The data are expressed as
mean±SEM. The number of dopamine cells recorded is given in
parentheses. *p<0.01, compared with control group [taken with
permission from Ref. (189)]. (D) Profile of dialysate serotonin and
dopamine concentrations during a 12-h extended-access cocaine
self-administration session.The mean±SEM presession baseline dialysate
concentrations of serotonin and dopamine were 0.98±0.1 nM and
5.3±0.5 nM, respectively (n=7) [taken with permission from Ref. (104)].
animals avoid an environment previously paired with an aver-
sive state. Such place aversions, when used to measure the aversive
stimulus effects of withdrawal, have been observed largely in the
context of opioids (132, 133). Systemic administration of a CRF1
receptor antagonist and direct intracerebral administration of a
peptide CRF1/CRF2 antagonist also decreased opioid withdrawal-
induced place aversions (134–136). These effects have been
hypothesized to be mediated by actions in the extended amyg-
dala. The selective CRF1 antagonist antalarmin blocked the place
aversion produced by naloxone in morphine-dependent rats (134),
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and a CRF peptide antagonist injected into the CeA also reversed
the place aversion produced by methylnaloxonium injected into
the CeA (135). CRF1 knockout mice failed to show conditioned
place aversion to opioid withdrawal and failed to show an opioid-
induced increase in dynorphin mRNA in the nucleus accumbens
(136).
A compelling test of the hypothesis that CRF-induced increases
in anxiety-like responses during drug withdrawal has motiva-
tional significance in contributing to negative emotional states
is the observation that CRF antagonists can reverse the elevation
in reward thresholds produced by drug withdrawal. Nicotine and
alcohol withdrawal-induced elevations in reward thresholds were
reversed by a CRF antagonist (137, 138). These effects have been
localized to both the CeA and nucleus accumbens shell (139).
Enhanced dynorphin action is hypothesized to mediate the
depression-like, aversive responses to stress, and dysphoric-like
responses during withdrawal from drugs of abuse (49, 56, 57,
140–145). For example, pretreatment with a κ-opioid receptor
antagonist blocked stress-induced analgesia and stress-induced
immobility (57), decreased anxiety-like behavior in the elevated
plus maze and open field, decreased conditioned fear in fear-
potentiated startle (145), and blocked depressive-like behavior
induced by cocaine withdrawal (140).
BRAIN STRESS SUBSTRATES THAT MEDIATE DRUG TAKING
WITH EXTENDED ACCESS
CORTICOTROPIN-RELEASING FACTOR, COMPULSIVE-LIKE DRUG
SEEKING, AND THE EXTENDED AMYGDALA
The ability of CRF antagonists to block the anxiogenic-like and
aversive-like motivational effects of drug withdrawal predicted
motivational effects of CRF antagonists in animal models of
extended access to drugs. CRF antagonists selectively blocked the
increased self-administration of drugs associated with extended
access to intravenous self-administration of cocaine (146), nico-
tine (77), and heroin [(147); Figure 8]. For example, sys-
temic administration of a CRF1 antagonist blocked the increased
self-administration of nicotine associated with withdrawal in
extended-access (23 h) animals (77).
Corticotropin-releasing factor antagonists also blocked the
increased self-administration of ethanol in dependent rats [(124);
Figure 8]. For example, exposure to repeated cycles of chronic
ethanol vapor produced substantial increases in ethanol intake
in rats during both acute withdrawal and protracted abstinence
[2 weeks post-acute withdrawal; (76, 148)]. Intracerebroventric-
ular administration of a CRF1/CRF2 antagonist blocked the
dependence-induced increase in ethanol self-administration dur-
ing both acute withdrawal and protracted abstinence (149).
Systemic injections of small-molecule CRF1 antagonists also
blocked the increased ethanol intake associated with acute with-
drawal (124) and protracted abstinence (150). When administered
directly into the CeA, a CRF1/CRF2 antagonist blocked ethanol
self-administration in ethanol-dependent rats (151). These effects
appear to be mediated by the actions of CRF on GABAergic
interneurons within the CeA, and a CRF antagonist administered
chronically during the development of dependence blocked the
development of compulsive-like responding for ethanol (116).
Altogether, these results suggest that CRF in the basal forebrain
may also play an important role in the development of the aver-
sive motivational effects that drive the increased drug-seeking
associated with cocaine, heroin, nicotine, and alcohol dependence.
DYNORPHIN, COMPULSIVE-LIKE DRUG SEEKING, AND THE EXTENDED
AMYGDALA
Recent evidence suggests that the dynorphin-κ opioid system
also mediates compulsive-like drug responding (methampheta-
mine, heroin, and alcohol) with extended access and dependence.
Evidence from our laboratory has shown a small-molecule κ
antagonist selectively blocked responding on a progressive-ratio
schedule for cocaine in rats with extended access (152). Even
more compelling is that excessive drug self-administration can
also be blocked by κ antagonists (152–155) and may be medi-
ated by the shell of the nucleus accumbens (156). However, the
neurobiological circuits involved in mediating the effects of acti-
vation of the dynorphin-κ opioid system on the escalation of
methamphetamine intake with extended access, remain unknown.
NPY, COMPULSIVE DRUG SEEKING, AND THE EXTENDED AMGYDALA
Neuropeptide Y is a neuropeptide with dramatic anxiolytic-like
properties localized to multiple brain regions but heavily inner-
vating the amygdala. It is hypothesized to have effects opposite
to CRF in the negative motivational state of withdrawal from
drugs of abuse and as such increases in NPY function may act
in opposition to the actions of increases in CRF (157). Significant
evidence suggests that activation of NPY in the CeA can block
the motivational aspects of dependence associated with chronic
ethanol administration. NPY administered intracerebroventricu-
larly blocked the increased drug intake associated with ethanol
dependence (158, 159). NPY also decreased excessive alcohol
intake in alcohol-preferring rats (160). Injection of NPY directly
into the CeA (161) and viral vector-enhanced expression of NPY
in the CeA also blocked the increased drug intake associated
with ethanol dependence (162). At the cellular level, NPY, like
CRF1 antagonists, blocks the increase in GABA release in the
CeA produced by ethanol and also when administered chronically
blocks the transition to excessive drinking with the development
of dependence (163). The role of NPY in the actions of other
drugs of abuse is limited, particularly with regard to dependence
and compulsive drug seeking. NPY 5 receptor knockout mice
have a blunted response to the rewarding effects of cocaine (164,
165), and NPY knockout mice show hypersensitivity to cocaine
self-administration (166). NPY itself injected intracerebroven-
tricularly facilitated heroin and cocaine self-administration and
induced reinstatement of heroin seeking in limited-access rats
(167, 168). An NPY Y2 antagonist, possibly acting presynaptically
to release NPY, blocked social anxiety associated with nicotine
withdrawal (169), and NPY injected intracerebroventricularly
blocked the somatic signs but not reward deficits associated with
nicotine withdrawal (170). However, the role of NPY in compul-
sive drug seeking with extended-access remains to be studied. The
hypothesis here would be that NPY is a buffer or homeostatic
response to between-system neuroadaptations that can return the
brain emotional systems to homeostasis (157, 171).
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FIGURE 8 | Effects of CRF1 antagonist on compulsive-like responding for
drugs of abuse in rats with extended access to drug (A).The effect of the
CRF1 receptor antagonist MPZP on operant self-administration of alcohol in
dependent and non-dependent rats. Testing was conducted when dependent
animals were in acute withdrawal (6–8 h after removal from vapors).
Dependent rats self-administered significantly more than non-dependent
animals, and MPZP dose-dependently reduced alcohol self-administration
only in dependent animals. The data are expressed as mean+SEM lever
presses for alcohol [taken with permission from Ref. (190)].
(B) Abstinence-induced escalation of nicotine intake is blocked by a CRF1
receptor antagonist. Effect of MPZP (s.c., −1 h) on nicotine self-administration
during the active period in rats given extended access to nicotine. *p< 0.05,
compared with baseline; #p<0.05, compared with after-abstinence vehicle
treatment; n=8). The data are expressed as mean+SEM lever presses for
nicotine [taken with permission from Ref. 77)]. (C) MPZP reduces cocaine
intake in ShA and LgA rats. The data are expressed as mean+SEM cocaine
intake (mg/kg). *p<0.05, **p<0.01, compared with vehicle [taken with
permission from Ref. (146)].
Corticotropin-releasing factor, stress, and the frontal cortex
Converging lines of evidence suggest that impairment of medial
PFC (mPFC) cognitive function and overactivation of the CeA
may be linked to the development of compulsive-like responding
for drugs of abuse during extended access (172–174). Extended
access to cocaine self-administration induced an escalated pattern
of cocaine intake associated with an impairment of working mem-
ory and decrease in the density of dorsomedial PFC (dmPFC) neu-
rons that lasted for months after cocaine cessation (172). Whereas
LgA and ShA rats exhibited a high percentage of correct responses
in the delayed non-matching-to-sample task under low cognitive
demand (delay< 10 s), increasing the working memory load (i.e.,
close to the capacity limit of working memory) by increasing the
delay from 10 to 70 and 130 s revealed a robust working memory
deficit in LgA rats. Furthermore, the magnitude of escalation of
cocaine intake was negatively correlated with working memory
performance in ShA and LgA rats with the 70- and 130-s delays
but not with the 10-s delay or with baseline performance during
training, demonstrating that the relationship between the esca-
lation of cocaine intake and behavioral performance in this task
was restricted to working memory performance under high cog-
nitive demand. The density of neurons and oligodendrocytes in
the dmPFC was positively correlated with working memory per-
formance. A lower density of neurons or oligodendrocytes in the
dmPFC was associated with more severe working memory impair-
ment. Working memory was also correlated with the density of
oligodendrocytes in the orbitofrontal cortex (OFC), suggesting
that OFC alterations after escalated drug intake may play a role
in working memory deficits. However, no correlation was found
between working memory performance and neuronal density in
the OFC, suggesting that OFC neurons may be less vulnerable to
the deleterious effects of chronic cocaine exposure than dmPFC
neurons. Thus, PFC dysfunction may exacerbate the loss of control
associated with compulsive drug use and facilitate the progression
to drug addiction.
Similar results have been observed in an animal model of
binge alcohol consumption, even before the development of
dependence. Using an animal model of escalation of alcohol
intake with chronic intermittent access to alcohol, in which rats
are given continuous (24 h per day, 7 days per week) or inter-
mittent (3 days per week) access to alcohol (20% v/v) using
a two-bottle choice paradigm, FBJ murine osteosarcoma viral
oncogene homolog (Fos) expression in the mPFC, CeA, hip-
pocampus, and nucleus accumbens were measured and corre-
lated with working memory and anxiety-like behavior (175).
Abstinence from alcohol in rats with a history of escalation of
alcohol intake specifically recruited GABA and CRF neurons in
the mPFC and produced working memory impairments asso-
ciated with excessive alcohol drinking during acute (24–72 h)
but not protracted (16–68 days) abstinence. The abstinence from
alcohol was associated with a functional disconnection of the
mPFC and CeA but not mPFC or nucleus accumbens. These
results show that recruitment of a subset of GABA and CRF neu-
rons in the mPFC during withdrawal and disconnection of the
PFC CeA pathway may be critical for impaired executive control
over motivated behavior, suggesting that dysregulation of mPFC
interneurons may be an early index of neuroadaptation in alcohol
dependence.
BRAIN STRESS SYSTEMS IN ADDICTION: AN ALLOSTATIC
VIEW
More importantly for the present thesis, as dependence and with-
drawal develop, brain anti-reward systems, such as CRF and
dynorphin, are recruited in the extended amygdala. We hypoth-
esize that this brain stress neurotransmitter that is known to
be activated during the development of excessive drug taking
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FIGURE 9 | Diagram of the hypothetical “within-system” and
“between-system” changes that lead to the “darkness within.” (Top)
Circuitry for drug reward with major contributions from mesolimbic
dopamine and opioid peptides that converge on the nucleus accumbens.
During the binge/intoxication stage of the addiction cycle, the reward
circuitry is excessively engaged, Middle. Such excessive activation of the
reward system triggers “within-system” neurobiological adaptations during
the withdrawal/negative affect stage, including activation of cyclic
adenosine monophosphate (cAMP) and cAMP response element-binding
protein (CREB), downregulation of dopamine D2 receptors, and decreased
firing of ventral tegmental area (VTA) dopaminergic neurons, Bottom. As
dependence progresses and the withdrawal/negative affect stage is
repeated, two major “between-system” neuroadaptations occur. One is
activation of dynorphin feedback that further decreases dopaminergic
activity. The other is recruitment of extrahypothalamic norepinephrine
(NE)-corticotropin-releasing factor (CRF) systems in the extended amygdala.
Facilitation of the brain stress system in the prefrontal cortex is
hypothesized to exacerbate the between-system neuroadaptations while
contributing to the persistence of the dark side into the
preoccupation/anticipation stage of the addiction cycle [taken with
permission from Ref. (191)].
comprises a between-system opponent process, and this activa-
tion is manifest when the drug in removed, producing anxiety,
hyperkatifeia, and irritability symptoms associated with acute
and protracted abstinence. Notably, however, there is evidence
of CRF immunoreactivity in the ventral tegmental area, and a
CRF1 receptor antagonist injected directly into the ventral tegmen-
tal area blocked the social stress-induced escalation of cocaine
self-administration (176). Altogether, these observations sug-
gest between-system/within-system neuroadaptations that were
originally hypothesized for dynorphin by Carlezon and Nestler
(177), in which activation of CREB by excessive dopamine and
opioid peptide receptor activation in the nucleus accumbens
triggers the induction of dynorphin to feed back to suppress
dopamine release. Thus, we hypothesize that anti-reward circuits
are recruited as between-system neuroadaptations (178) during
the development of addiction and produce aversive or stress-like
states (179–181) via two mechanisms: direct activation of stress-
like, fear-like states in the extended amygdala (CRF) and indirect
activation of a depression-like state by suppressing dopamine
(dynorphin).
A critical problem in drug addiction is chronic relapse, in
which addicted individuals return to compulsive drug taking
long after acute withdrawal. This corresponds to the preoccupa-
tion/anticipation stage of the addiction cycle outlined above. Koob
and Le Moal also hypothesized that the dysregulations that com-
prise the “dark side” of drug addiction persist during protracted
abstinence to set the tone for vulnerability to “craving” by activat-
ing drug-, cue-, and stress-induced reinstatement neurocircuits
that are now driven by a reorganized and possibly hypofunction-
ing prefrontal system. The hypothesized allostatic, dysregulated
reward,and sensitized stress state produces the motivational symp-
toms of acute withdrawal and protracted abstinence and provides
the basis by which drug priming, drug cues, and acute stressors
acquire even more power to elicit drug-seeking behavior (92).
Thus, the combination of decreases in reward system function and
recruitment of anti-reward systems provides a powerful source
of negative reinforcement that contributes to compulsive drug-
seeking behavior and addiction. A compelling argument can be
made that the neuroplasticity that charges the CRF stress system
may indeed begin much earlier that previously thought via stress
actions in the PFC.
The overall conceptual theme argued here is that drug addiction
represents an excessive and prolonged engagement of homeostatic
brain regulatory mechanisms that regulate the response of the
body to rewards and stressors. The dysregulation of the incen-
tive salience systems may begin with the first administration of
drug (182), and the dysregulation of the stress axis may begin
with the binge and subsequent acute withdrawal, triggering a
cascade of changes, from activation of the HPA axis to activa-
tion of CRF in the PFC to activation of CRF in the extended
amygdala to activation of dynorphin in the ventral striatum
(Figure 9). This cascade of overactivation of the stress axis rep-
resents more than simply a transient homeostatic dysregulation;
it also represents the dynamic homeostatic dysregulation termed
allostasis.
Repeated challenges, such as with drugs of abuse, lead to
attempts of the brain stress systems at the molecular, cellular,
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and neurocircuitry levels to maintain stability but at a cost.
For the drug addiction framework elaborated here, the resid-
ual decrease in the brain reward systems and activation of the
brain stress systems to produce the consequent negative emo-
tional state is termed an allostatic state (15). This state represents
a combination of recruitment of anti-reward systems and con-
sequent chronic decreased function of reward circuits, both of
which lead to the compulsive drug seeking and loss of control
over intake. How these systems are modulated by other known
brain emotional systems localized to the basal forebrain, where
the ventral striatum and extended amygdala project to convey
emotional valence, how frontal cortex dysregulations in the cog-
nitive domain are linked to impairments in executive function to
contribute to the dysregulation of the extended amygdala, and
how individuals differ at the molecular-genetic level of analysis
to convey loading on these circuits remain challenges for future
research.
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